on
19.1.08
with
0 comments
New drugs and new indications of already approved drugs by FDA in 2006-07
Aliskiren:
- New class of Renin Inhibitors
- Once daily oral formulation
- Mono therapy or in combination with other drugs for treatment of high B.P
Inhaled Insulin:
- Management of type I and type II Diabetes Mellitus
Cinacalcet:
- Treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance dialysis therapy.
Posaconazole:
- Triazole antifungal Agent
- Prevention of invasive aspergillus and candida infection in immunosuppressed individuals.
Darunavir:
- Inhibitor of HIV-I protease
- Selectively inhibits cleavage of HIV encoded Gag-Pol polyproteins in infected cells.
Lisdexampfetamine:
- Pro drug of dextroamfetamine
- In Attention Deficit/Hyperactivity Disorders in the 6-12 year age group
Cyclobenzaprine:
- Extended release formulation of skeletal muscle relaxant
- As an adjunct to rest and physiotherapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Erlotinib:
- Human Epithelial Grouth Factor type I/Epidermal Growth Factor Receptor [HER1/EGFR] inhibitor.
- In treatment of non small cell Lung and Pancreatic cancer.
Category:
Pharmacology Notes
POST COMMENT
0 comments:
Post a Comment